|
Carmona-Bayonas A, Jiménez-Fonseca P. CISNE or MASCC, which predictor is really the weakest in febrile neutropenia? Eur J Intern Med. 2018 Apr;50:e33-e34. doi: 10.1016/j.ejim.2017.11.009. Epub 2017 Nov 20. PubMed PMID: 29157884.
AÑO: 2018; IF: 3.66
|
29157884
|
Carmona-Bayonas A, Gordo F, Beato C, Castaño Pérez J, Jiménez-Fonseca P, Virizuela Echaburu J, Garnacho-Montero J. Complexity and uncertainty in the critical care of cancer patients in the era of immunotherapy and targeted therapies. Med Intensiva. 2018 Dec;42(9):570-571. doi: 10.1016/j.medin.2018.05.001. Epub 2018 Jun 11. English, Spanish. PubMed PMID: 29903636.
AÑO: 2018; IF: 1.982
|
|
Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364. Epub 2018 Jan 12. PubMed PMID: 29330208; PubMed Central PMCID: PMC5896708.
AÑO: 2018; IF: 5.252
|
|
Carmona-Bayonas A, Jiménez Fonseca P, Virizuela Echaburu J. Tapentadol for Cancer Pain Management: A Narrative Review. Pain Pract. 2017 Nov;17(8):1075-1088. doi: 10.1111/papr.12556. Epub 2017 Feb 25. Review. PubMed PMID: 28084045.
AÑO: 2017; IF: 2.187
|
|
Carmona-Bayonas A, Jiménez-Fonseca P, Castañón E, Ramchandani-Vaswani A, Sánchez-Bayona R, Custodio A, Calvo-Temprano D, Virizuela JA. Chronic opioid therapy in long-term cancer survivors. Clin Transl Oncol. 2017 Feb;19(2):236-250. doi: 10.1007/s12094-016-1529-6. Epub 2016 Jul 21. Review. PubMed PMID: 27443415.
AÑO: 2017; IF: 2.392
|